Rhumbline Advisers Acquires 15,582 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Rhumbline Advisers grew its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 7.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 215,055 shares of the biopharmaceutical company’s stock after acquiring an additional 15,582 shares during the quarter. Rhumbline Advisers owned about 0.14% of TG Therapeutics worth $3,826,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of TGTX. Principal Financial Group Inc. lifted its position in TG Therapeutics by 3.9% in the 1st quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock worth $538,000 after buying an additional 1,322 shares during the last quarter. Swiss National Bank increased its stake in TG Therapeutics by 0.5% in the 1st quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock worth $4,321,000 after purchasing an additional 1,500 shares during the period. nVerses Capital LLC increased its stake in TG Therapeutics by 34.9% in the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 1,500 shares during the period. Pingora Partners LLC purchased a new position in TG Therapeutics in the 4th quarter worth approximately $27,000. Finally, ProShare Advisors LLC increased its stake in TG Therapeutics by 8.5% in the 1st quarter. ProShare Advisors LLC now owns 24,914 shares of the biopharmaceutical company’s stock worth $379,000 after purchasing an additional 1,961 shares during the period. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 4.9 %

TG Therapeutics stock opened at $24.89 on Tuesday. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The business’s fifty day simple moving average is $21.73 and its two-hundred day simple moving average is $18.15. TG Therapeutics, Inc. has a 12 month low of $6.46 and a 12 month high of $25.87. The company has a market capitalization of $3.85 billion, a price-to-earnings ratio of 108.22 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The firm had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company’s quarterly revenue was up 357.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.34) earnings per share. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on TGTX. The Goldman Sachs Group lifted their price target on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $49.00 price target on shares of TG Therapeutics in a research report on Tuesday, August 6th. Finally, B. Riley lifted their price target on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $31.83.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.